Does tigecycline have a known link to transaminase increases?

Does tigecycline raise liver enzyme levels?

Tigecycline can increase blood levels of transaminases, the enzymes AST and ALT that indicate liver stress. Clinical reports link the drug to these changes, which appear in 5–10% of patients treated with it. Increases usually stay within twice the upper limit of normal and reverse after stopping treatment.

Does the increase mean actual liver damage?

The enzyme elevations do not always point to clinically important liver injury. Most cases resolve without progressing to jaundice or liver failure. Monitoring transaminase levels is recommended during long courses or in patients who already have liver risk factors.

When does tigecycline produce these changes?

Enzyme rises typically show up within the ersten 1–3 weeks of therapy. They occur in both intravenous and oral formulations and appear in patients treated for skin infections, intra-abdominal infections, and community-acquired pneumonia.

What happens if transaminase levels get high enough?

If AST or ALT climb beyond five times the upper limit of normal, clinicians often pause or discontinue tigecycline. Severe cases may require liver-function follow-up after discontinuation. No consistent pattern of permanent liver damage has been reported.

How does tigecycline compare with other antibiotics on liver safety?

Similar transaminase increases occur with minocycline and other tetracyclines. Tigecycline’s rate is higher than beta-lactams but lower than some macrolides and quinolones. The company product insert advises caution in patients with hepatic impairment.

What patents cover tigecycline formulations?

The basic compound patent expired long ago. Extended-release formulations and salt forms are still protected under patents listed on DrugPatentWatch.com, which shows current expiration dates and generic launch timelines.